scholarly journals Survey of AREDS2 Formula Intake in Korean Patients with Age-related Macular Degeneration

2021 ◽  
Vol 62 (11) ◽  
pp. 1502-1508
Author(s):  
Jeong Ho Na ◽  
Jae Wan Lim ◽  
Jong Wook Bang ◽  
Kang Yeun Pak ◽  
Hyun Woong Kim
Keyword(s):  
Macular Degeneration ◽  
Older Patients ◽  
Disease Duration ◽  
Education Level ◽  
Age Related Macular Degeneration ◽  
Prospective Survey ◽  
Age Related ◽  
Low Education ◽  
Antioxidant Supplements ◽  
Disease Perception

Purpose: To investigate the use of second AREDS2 formula in patients with intermediate or advanced age-related macular degeneration.Methods: A prospective survey was conducted between December 2019 and July 2020. The questionnaire consisted of 24 questions on demographics, disease perception, and formula intake.Results: The survey included 100 patients (males, 56%; age [>60 years], 89%). We found that 66%, 84%, and 93% of patients had a good understanding of their disease, had stopped smoking, and were aware of the need for antioxidant supplements; 58% of patients were aware of the supplement they were prescribed, and 63.8% (37% of total) were using the AREDS2 formula. Only 8% of patients had knowledge regarding the supplement ingredients, and 91% consumed the supplement daily. Patients with long disease duration used supplements less frequently (p < 0.05). Older patients and those with a low education level had a limited perception of the disease (p < 0.05).Conclusions: In this prospective survey, some patients consumed supplements other than the AREDS2 formula. Further studies are required to determine ways to increase the use of the AREDS2 formula.

Antioxidant Supplements Prevent Oxidation of Cysteine/Cystine Redox in Patients With Age-Related Macular Degeneration

2005 ◽  
Vol 140 (6) ◽  
pp. 1020-1026 ◽  
Author(s):  
Siobhan E. Moriarty-Craige ◽  
Joanne Adkison ◽  
Michael Lynn ◽  
Gary Gensler ◽  
Susan Bressler ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Antioxidant Supplements

scholarly journals Antioxidant supplements in age-related macular degeneration: are they actually beneficial?

2021 ◽  
Vol 13 ◽  
pp. 251584142110304
Author(s):  
Mousumi Banerjee ◽  
Rohan Chawla ◽  
Atul Kumar
Keyword(s):  
Macular Degeneration ◽  
Visual Loss ◽  
Epidemiological Studies ◽  
Age Related Macular Degeneration ◽  
Age Group ◽  
Inappropriate Use ◽  
Age Related ◽  
False Sense ◽  
Antioxidant Supplements

Age-related macular degeneration (ARMD) is one of the prominent causes of central visual loss in the older age group in the urbanized, industrialized world. In recent years, many epidemiological studies and clinical trials have evaluated the role of antioxidants and micronutrients to prevent the progression of ARMD. In this article, we review some of these major studies. In addition, we review the absorption and bioavailability and possible undesirable effects of these nutrients after ingestion. The role of genotypes and inappropriate use of these supplements are also discussed. From all the above evidence, we conclude that it may not be prudent to prescribe these formulations without a proper assessment of the individual’s health and dietary status. The effectiveness of all the components in antioxidant formulations is controversial. Thus, these supplements should not be prescribed just for the purpose of providing patients some kind of therapy, which may give a false sense of mental satisfaction.

scholarly journals Predictors of functional outcome of antiangiogenic therapy in neovascular age-related macular degeneration

2020 ◽  
Vol 13 (4) ◽  
pp. 7-13
Author(s):  
Alexandr S. Kharakozov ◽  
Alexey N. Kulikov ◽  
Dmitrii S. Maltsev
Keyword(s):  
Visual Acuity ◽  
Macular Degeneration ◽  
Functional Outcome ◽  
Disease Duration ◽  
Antiangiogenic Therapy ◽  
Age Related Macular Degeneration ◽  
Ellipsoid Zone ◽  
Age Related ◽  
Treatment Naïve

Aim.To study predictive factors for functional outcome of aflibercept intravitreal antiangiogenic therapy in patients with neovascular age-related macular degeneration (nAMD). Material and methods.Thirty-six treatment naive nAMD patients (45 eyes, 26 females and 10 males, with a mean age of 74.4 10.9 years) were included in this study. All patients received 3 monthly aflibercept injections followed by 4 bimonthly aflibercept injections. Demographic characteristics, baseline best corrected visual acuity (BCVA), central retinal thickness (CRT), and structural retinal changes on optical coherence tomography (OCT) scans were evaluated for the correlation with BCVA after 10 months follow-up. Results.At the end of the follow-up period, the mean BCVA increased statistically significantly from 31 15 (~0.32) letters at baseline to 37 14 (~0.4) letters (p= 0.003). CRT at baseline and at the end of follow-up was 357 110 and 269 70 m (p 0.001), respectively. Final BCVA correlated statistically significantly with baseline BCVA (r= 0.62,p 0.0001), baseline CRT (r= 0.48,p= 0.001), and disease duration from the appearance of complaints until the therapy start (r= 0.32,p= 0.03). Structural macular changes on the OCT scans were not related to final BCVA (p 0.05) apart from the status of the ellipsoid zone (p 0.001). Final BCVA was statistically significantly lower in males than in females (34.7 14.0 (~0.4) and 45.0 9.2 (~0.63) letters, respectively,p= 0.03). Conclusion.Baseline visual acuity, gender, CRT, disease duration from the appearance of complaints until the therapy start, and status of the ellipsoid zone are predictive for the functional outcome in wet AMD patients.

Oxidation and age-related macular degeneration: insights from molecular biology

2010 ◽  
Vol 12 ◽  
Author(s):  
Sam Khandhadia ◽  
Andrew Lotery
Keyword(s):  
Macular Degeneration ◽  
Genetic Manipulation ◽  
Age Related Macular Degeneration ◽  
Current Therapy ◽  
Genetic Studies ◽  
Antioxidant Genes ◽  
Age Related ◽  
Antioxidant Supplements ◽  
Developed World

Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world. It is a multifactorial disease, and current therapy predominantly limits damage only when it has already occurred. The macula is a source of high metabolic activity, and is therefore exposed to correspondingly high levels of reactive oxygen species (ROS). With age, the balance between production of ROS and local antioxidant levels is shifted, and damage ensues. Systemic ROS and antioxidant levels in AMD reflect these local processes. Genetic studies investigating mutations in antioxidant genes in AMD are inconclusive and further studies are indicated, especially to determine the role of mitochondria. Oral antioxidant supplements could be beneficial, and diet modification may help. Future treatments might either increase antioxidant capacity or reduce the production of ROS, using methods such as genetic manipulation. This article reviews the role of oxidative stress in AMD and the potential therapies that might have a role in preventing the blindness resulting from this disease.

scholarly journals Depression, Anxiety, Somatization Disorder, and Adjustment Disorder in Older Patients with Exudative Age-related Macular Degeneration

2021 ◽  
Vol 62 (8) ◽  
pp. 1069-1075
Author(s):  
Hee Chul Lee ◽  
Hyewon Nam ◽  
Dongwoo Kang ◽  
Myeong In Yeom
Keyword(s):  
Macular Degeneration ◽  
Older Patients ◽  
Adjustment Disorder ◽  
Age Related Macular Degeneration ◽  
Somatization Disorder ◽  
Psychiatric Disease ◽  
Control Group ◽  
Exudative Amd ◽  
Age Related ◽  
Prevalence Of Depression

Purpose: The aim of this study was to analyze the prevalence of depression, anxiety, somatization disorder, and adjustment disorder in older patients diagnosed with exudative age-related macular degeneration (AMD) and to evaluate the relationship between exudative AMD and psychological disease.Methods: The 2016 Health Insurance Review and Assessment Service-Aged Patient Sample was applied in this study. The subjects were divided into two groups: AMD patients undergoing intravitreal injection treatment and a control group. Comorbidities were evaluated using the Charlson Comorbidity Index.Results: A total of 1,319,052 subjects were selected, of which 3,134 were in the exudative AMD group receiving intravitreal injections. The average age of the subjects was 74.7 ± 6.7 years, and 41.8% were male. In patients with exudative AMD, the prevalence of depression, anxiety, somatization disorder, and adjustment disorder were 16%, 20%, 0.5%, and 0.4%, respectively; in particular, the prevalence of depression and adjustment disorder were significantly higher than in the control group. In multivariate regression analysis, exudative AMD was a significant factor of depression (odds ratio [OR] 1.2, 95% confidence interval [CI] 1.08-1.31, p < 0.001) and adjustment disorder (OR 2.47, 95% CI 1.47-4.18, p < 0.001). However, the association between AMD and anxiety or somatization disorder was not statistically significant.Conclusions: Exudative AMD showed a significant association with psychiatric disease, such as depression, and requires close clinical attention.

Age related macular degeneration (ARMD) – pathophysiological and clinical features and therapeutic concepts

2001 ◽  
Vol 58 (1) ◽  
pp. 28-35 ◽  
Author(s):  
Ursula Körner-Stiefbold
Keyword(s):  
Macular Degeneration ◽  
Clinical Features ◽  
Altersbedingte Makuladegeneration ◽  
Age Related Macular Degeneration ◽  
Genetische Faktoren ◽  
Age Related ◽  
Therapeutic Concepts

Die altersbedingte Makuladegeneration (AMD) ist eine der häufigsten Ursachen für einen irreversiblen Visusverlust bei Patienten über 65 Jahre. Nahezu 30% der über 75-Jährigen sind von einer AMD betroffen. Trotz neuer Erkenntnisse in der Grundlagenforschung ist die Ätiologie, zu der auch genetische Faktoren gehören, noch nicht völlig geklärt. Aus diesem Grund sind die Behandlungsmöglichkeiten zum jetzigen Zeitpunkt noch limitiert, so dass man lediglich von Therapieansätzen sprechen kann. Die derzeit zur Verfügung stehenden Möglichkeiten wie medikamentöse, chirurgische und laser- und strahlentherapeutische Maßnahmen werden beschrieben.

Sign in / Sign up

Export Citation Format

Share Document